Dialysis rides and more: the lasting human impact of Trump's funding freeze

Turn off the spigot, even briefly, and it's felt far from Washington, D.C.

February 18, 2025 Check out STAT+

Sponsored By

Steve Helber/AP The lasting human impact of Trump funding freeze: An 86-year-old's ride to dialysis now feels tenuous Trump federal freeze felt by a West Virginia patient, Ohio addiction counselor, Kansas rural health advocate: assessing real-life impact of Trump policies. By Eric Boodman STAT+ | FDA's former top food official says Trump firings are 'dismantling' the division Jim Jones, until recently the FDA's deputy commissioner for foods, said the termination of employees mean the division is taking "a big step backward." By Matthew Herper Opinion: The 'disease detectives' dodged a bullet — but another might be coming The fact that EIS's existence was in jeopardy at all highlights the precariousness of our public health infrastructure. By Denis Nash Manuel Balce Ceneta/AP STAT+ | FDA's head of device safety among employees terminated in 'challenging' weekend The cuts hit the FDA's medical device center particularly hard, including reviewers and experts on AI-enabled medical technology. By Lizzy Lawrence STAT+ | Duchenne gene therapy from Solid Biosciences produces promising results in early study The company is one of several trying to develop an improved gene therapy for the genetic muscle wasting condition. By Jason Mast STAT+ | XRHealth makes another acquisition, aiming to be a leading virtual provider using VR XRHealth is acquiring RealizedCare, a company that couples immersive experiences with coaches for chronic pain management. By Mario Aguilar Courtesy Daniel Reinish Opinion: What my sister's life and death taught me about the NIH A decade ago, my sister died at the National Institutes of Health. I still have faith in them, and I hope that the country does, too. By Ariel Reinish STAT+ | Biogen partners with Stoke Therapeutics on drug for severe epilepsy Called zorevunersen, the Stoke drug has shown potential to become the first treatment to target the underlying, genetic cause of the condition. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser